Blood Advances
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis..
8:5993-6002.
2024
-
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial..
8:5790-5795.
2024
-
The impact of different doses of oral iron supplementation during pregnancy: a pilot randomized trial..
8:5683-5694.
2024
-
ASH living guidelines on use of anticoagulation for thromboprophylaxis in patients with COVID-19: executive summary..
bloodadvances.2024014219.
2024
-
What's in a name: defining pediatric refractory ITP.
8:5112-5117.
2024
-
Thrombophilia testing: does practice follow guidelines?.
8:4948-4949.
2024
-
Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion.
8:4169-4180.
2024
-
ASH Guideline Oversight Subcommittee Response to Jacobs et al regarding Industry Payments to ASH Guideline Panelists.
8:3553-3554.
2024
-
Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines.
8:3596-3606.
2024
-
The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia.
8:3578-3582.
2024
-
Distinguishing ASH clinical practice guidelines from other forms of ASH clinical advice.
8:2960-2963.
2024
-
Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP.
8:1869-1879.
2024
-
Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure.
8:732-735.
2024
-
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.
7:7101-7138.
2023
-
ASH Clinical Practice Guidelines: strategies to stay up-to-date.
7:6707-6709.
2023
-
Histidine-rich glycoprotein attenuates catheter thrombosis.
7:5651-5660.
2023
-
Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee.
7:4323-4326.
2023
-
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence.
7:3783-3792.
2023
-
American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America.
7:3005-3021.
2023
-
Huynh A, Arnold DM, Michael JV, et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 2023;7(2):246-250..
7:3113-3113.
2023
-
Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
7:2746-2757.
2023
-
Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225..
7:1671-1671.
2023
-
Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021;5(20):3951-3959..
7:811.
2023
-
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S.
7:246-250.
2023
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.
6:4975-4982.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.
6:4915-4923.
2022
-
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
6:4816-4820.
2022
-
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.
6:4516-4523.
2022
-
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism.
6:4605-4616.
2022
-
Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.
6:4137-4146.
2022
-
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia.
6:4228-4235.
2022
-
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
6:3991-3995.
2022
-
American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America.
6:3636-3649.
2022
-
Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.
6:3735-3745.
2022
-
SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia.
6:2250-2253.
2022
-
Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency.
6:1844-1853.
2022
-
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.
6:785-792.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.
6:664-671.
2022
-
Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review.
6:544-567.
2022
-
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
6:228-237.
2022
-
Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
6:121-128.
2022
-
von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
6:62-71.
2022
-
Consensus statement for the perinatal management of patients with α thalassemia major.
5:5636-5639.
2021
-
Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy.
5:5023-5031.
2021
-
Stuttering priapism in a patient with sickle cell trait treated with automated red cell exchange transfusion.
5:5020-5022.
2021
-
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
5:4980-4991.
2021
-
How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines.
5:4721-4726.
2021
-
A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations.
5:3931-3936.
2021
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.
5:3951-3959.
2021
-
Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia.
5:4256-4264.
2021
-
Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein.
5:3540-3551.
2021
-
Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis.
5:3120-3133.
2021
-
ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America.
5:3032-3046.
2021
-
Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context.
5:3047-3052.
2021
-
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism.
5:2237-2244.
2021
-
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
5:927-974.
2021
-
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.
5:1081-1091.
2021
-
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.
5:872-888.
2021
-
Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort.
5:451-458.
2021
-
von Willebrand disease: proposing definitions for future research..
5:565-569.
2021
-
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
5:280-300.
2021
-
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
5:301-325.
2021
-
Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.
4:5616-5630.
2020
-
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study.
4:5373-5377.
2020
-
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.
4:5184-5193.
2020
-
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.
4:4929-4944.
2020
-
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).
4:4632-4639.
2020
-
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism.
4:4693-4738.
2020
-
Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism.
4:4296-4311.
2020
-
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
4:3528-3549.
2020
-
Iron deficiency following bariatric surgery: a retrospective cohort study.
4:3639-3647.
2020
-
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure.
4:3520-3527.
2020
-
Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.
4:3368-3377.
2020
-
Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia.
4:2962-2966.
2020
-
Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism.
4:2798-2809.
2020
-
Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment.
4:2557-2566.
2020
-
Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis.
4:2779-2788.
2020
-
Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry).
4:2460-2467.
2020
-
Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy.
4:2516-2522.
2020
-
Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.
4:2351-2365.
2020
-
A user guide to the American Society of Hematology clinical practice guidelines.
4:2095-2110.
2020
-
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.
4:2011-2017.
2020
-
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.
4:1512-1517.
2020
-
Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy.
4:1250-1264.
2020
-
Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.
4:1539-1553.
2020
-
Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines.
4:953-968.
2020
-
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
4:728-739.
2020
-
A practical approach to evaluating postoperative thrombocytopenia.
4:776-783.
2020
-
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
4:629-637.
2020
-
Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.
4:500-513.
2020
-
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
4:560-572.
2020
-
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
4:327-355.
2020
-
2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.
3:3945-3950.
2019
-
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
3:3829-3866.
2019
-
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.
3:3898-3944.
2019
-
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.
3:3867-3897.
2019
-
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
3:3780-3817.
2019
-
Thrombus stability explains the factor V Leiden paradox: a mouse model.
3:3375-3378.
2019
-
BCL2L1 is associated with γ-globin gene expression.
3:2995-3001.
2019
-
A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation.
3:1638-1646.
2019
-
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
3:1226-1229.
2019
-
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis.
3:789-796.
2019
-
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis.
3:158-167.
2019
-
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.
2:3292-3316.
2018
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism.
2:3226-3256.
2018
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
2:3360-3392.
2018
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
2:3257-3291.
2018
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
2:3198-3225.
2018
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.
2:3317-3359.
2018
-
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
2:3193-3195.
2018
-
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
2:3149-3154.
2018
-
Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia.
2:3155-3162.
2018
-
The value of clinical practice guidelines in hematology.
2:3196-3197.
2018
-
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
2:1935-1945.
2018
-
Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development.
2:1998-2011.
2018
-
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances.
2:1806-1806.
2018
-
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
2:1449-1458.
2018
-
Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
2:769-776.
2018
-
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
2:788-796.
2018
-
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
2:529-533.
2018
-
Designing a successful capacity-building program in a low-income country: the St. Joseph’s Health System–McMaster–Makerere International Outreach Program Collaboration for Uganda.
1:1-4.
2017
-
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry.
1:2414-2420.
2017
-
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
1:1827-1838.
2017
-
Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.
1:1037-1046.
2017
-
The direct oral anticoagulants: can we finally stop using rat poison?.
1:980-980.
2017
-
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis.
1:772-778.
2017
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)